Tuesday's Health Winners & Losers
Positive trial news pumped up shares of a few biotech companies, including Cortex Pharmaceuticals (COR), on Tuesday while others bared their earnings.
Cortex Pharmaceuticals said Tuesday that the Food and Drug Administration gave it a green light to resume enrollment in its Alzheimer's treatment Ampakine cx717. On the basis of data submitted in April, the agency has approved a protocol with all dose levels for the study, after previously putting a hold on 600-mg and 1200-mg doses. The limitations were related to concerns over data from preclinical animal trials, according to the company. Cortex rose 64 cents, or 24%, to $3.31.
Another winner, Durect (DRRX), announced positive results in a phase IIb clinical trial of Posidur for post-operative pain in patients undergoing inguinal hernia repair. It was the study that Durect and Nycomed are basing the advancement of Posidur into phase III trials, and the results trigger an $8 million milestone payment from Nycomed.
Durect, which gained 68 cents, or 18.2%, to $4.41, said it has scheduled an end-of-phase II meeting with the FDA in preparation for Posidur's phase III program.Also, Nastech Pharmaceuticals (NSTK) was issued two U.S. patents for its Parathyroid Hormone Nasal Spray to treat osteoporosis and PYY nasal spray for treatment of obesity. Nastech added $1, or 8.4%, to $12.89. Durect and Nastech Pharmaceuticals are both components of the Nasdaq Biotechnology index, which was up 0.45, or 0.05%, to 818.69.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV